Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
BBIO BridgeBio Pharma
9.110+0.260+2.94%
Close
01/27 16:00 ET
8.710-0.400-4.39%
Post Mkt Price 01/27 17:58 ET
High
9.260
Open
8.750
Turnover
8.80M
Low
8.750
Pre Close
8.850
Volume
975.13K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
SVB Securities Adjusts Price Target on BridgeBio Pharma to $19 From $23, Maintains Outperform Rating
09:30 AM EST, 01/23/2023 (MT Newswires) -- BridgeBio Pharma (BBIO) has an average buy rating and price target range of $15 to $32, according to analysts polled by Capital IQ.
SVB Securities Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
BridgeBio Pharma Is Maintained at Outperform by SVB Leerink
BridgeBio Pharma Price Target Cut to $19.00/Share From $23.00 by SVB Leerink
BridgeBio Pharma Price Target Cut to $19.00/Share From $23.00 by SVB Leerink
BridgeBio Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/23/2023 125.39% SVB Leerink $23 → $19 Maintains Outperform 11/18/2022 125.39% JP Morgan $20 → $19 Maint
SVB Leerink Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $19
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma with a Outperform and lowers the price target from $23 to $19.
Benitec Biopharma (NASDAQ:BNTC) Versus BridgeBio Pharma (NASDAQ:BBIO) Critical Analysis
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) and Benitec Biopharma (NASDAQ:BNTC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesse
Fly Insider: Travelzoo, Box Among Week's Notable Insider Trades
Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $920,400.00 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CEO Neil Kumar sold 120,000 shares of the stock in a transaction that occurred on Thursday, January 5th. The shares were sold at an average price of
BridgeBio Pharma (BBIO) Receives a Buy From SVB Securities
Company Overview
More
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
CEO： Mr. Neil Kumar, PhD
Market： NASDAQ
Listing Date： 06/27/2019
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet